Title: Professor Doctor Family Name(s): Maack First Name(s): Christoph Age: 51



Application for the following position in the HFA Board or Nominating Committee: Nominating Committee member

Place of work

If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.

Institute/organisation:	University Clinic Würzburg
Department:	Comprehensive Heart Failure Center
Address:	Am Schwarzenberg 15, Building A15
Post code / Zip:	97078 Würzburg
Country:	Germany

General Curriculum Vitae (500 words max)

Please also include your H index and top 5 to 10 publications in the last 5 years

Christoph Maack received his MD at the University of Cologne (Germany) in 2000. From 2000 to 2017, he worked at the Department of Cardiology at the University of the Saarland in Homburg, Germany (Director: Professor Michael Böhm), first as an Assistant- (2000-2002; 2005-2012) and from 2012 to 2017 as a Senior Physician. From 2002 to 2005, he interrupted his clinical education and performed a post-doctoral research fellowship in the Department of Cardiology at Johns Hopkins University in Baltimore, MD, US. From 2006 on, he established his own working group in Homburg with the support of the Emmy Noether Programme of the German Research Foundation (DFG). From 2012 on, he held a DFG Heisenberg Professorship on Cardiovascular Physiology and Bioenergetics in Homburg, Germany. Since 2017, Professor Maack holds the Chair for Translational Research at- and is the Spokesperson of the Comprehensive Heart Failure Center (CHFC) at the University Clinic in Würzburg, Germany.

Christoph Maack's work focuses on cellular defects in hereditary and acquired forms of heart failure, with a special emphasis on the mechanisms of contractile, mitochondrial and metabolic dysfunction in heart failure. For his research, Professor Maack was awarded numerous awards, the most relevant being the Albert-Fraenkel- (2014) and the Arthur-Weber Awards (2015) of the German Cardiac Society and the Keith Reimer Distinguished Lecture of the International Society for Heart Research (ISHR), held during the ISHR World Congress in Beijing, China.

Prof. Maack is an Associate Editor for *Circulation Research* and an Advisor *to Nature Reviews Cardiology*. Furthermore, he is on the Editorial Board of *Basic Research in Cardiology*, *Clinical Research in Cardiology* and *JMCC Plus*.

Publication record

>200 publications in total, **11.836 (Scopus) / 17.570 citations (Google)**, H-factor 51 (Scopus)/ 61 (Google Scholar; February 16th, 2024)

5 most relevant publications related to this application:

Bertero E, Nickel A, Kohlhaas M, Hohl M, Sequeira V, Brune C, Schwemmlein J, Abesser M, Schuh K, Kutschka I, Carlein C, Münker K, Atighetchi S, Müller A, Kazakov A, Kappl R, von der Malsburg K, van der Laan M, Schiuma AF, Böhm M, Laufs U, Hoth M, Rehling P, Kuhn M, Dudek J, von der Malsburg A, Prates Roma L and <u>Maack C</u>.

Loss of Mitochondrial Ca²⁺ Uniporter Limits Inotropic Reserve and Provides Trigger and Substrate for Arrhythmias in Barth Syndrome Cardiomyopathy.

Circulation. 2021;144:1694-1713.

<u>Maack C</u>, Eschenhagen T, Hamdani N, Heinzel FR, Lyon AR, Manstein DJ, Metzger J, Papp Z, Tocchetti CG, Birhan Yilmaz M, Anker SD, Balligand JL, Bauersachs J, Brutsaert D, Carrier L, Chlopicki S, Cleland JG, de Boer RA, Dietl A, Fischmeister R, Harjola VP, Heymans S, Hilfiker-Kleiner D, Holzmeister J, de Keulenaer G, Limongelli G, Linke WA, Lund LH, Masip J, Metra M, Mueller C, Pieske B, Ponikowski P, Ristic A, Ruschitzka F, Seferovic PM, Skouri H, Zimmermann WH and Mebazaa A.

Treatments targeting inotropy. A position paper of the Committees on Translational Research and Acute Heart Failure of the Heart Failure Association of the European Society of Cardiology *Eur Heart J.* 2019;40:3626-3644.

<u>Maack C</u>, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, Paulus WJ, Rossignol P, Taegtmeyer H, Bauersachs J, Bayes-Genis A, Brutsaert D, Bugger H, Clarke K, Cosentino F, De Keulenaer G, Dei Cas A, Gonzalez A, Huelsmann M, Iaccarino G, Lunde IG, Lyon AR, Pollesello P, Rena G, Riksen NP, Rosano G, Staels B, van Laake LW, Wanner C, Farmakis D, Filippatos G, Ruschitzka F, Seferovic P, de Boer RA and Heymans S.

Heart failure and diabetes: metabolic alterations and therapeutic interventions. A state-of-theart review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology

Eur Heart J. 2018;39:4243-4254.

Nickel AG, von Hardenberg A, Hohl M, Löffler JR, Kohlhaas M, Becker J, Reil JC, Kazakov A, Bonnekoh J, Stadelmaier M, Puhl SL, Wagner M, Bogeski I, Cortassa S, Kappl R, Pasieka B, Lafontaine M, Lancaster CR, Blacker TS, Hall AR, Duchen MR, Kaestner L, Lipp P, Zeller T, Müller C, Knopp A, Laufs U, Böhm M, Hoth M, <u>Maack C.</u>

Reversal of Mitochondrial Transhydrogenase Causes Oxidative Stress in Heart Failure. *Cell Metab.* 2015;22:472-84.

Kohlhaas M, Liu T, Knopp A, Zeller T, Ong MF, Böhm M, O'Rourke B, <u>Maack C.</u> Elevated cytosolic Na⁺ increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes.

Circulation. 2010;121:1606-13.

Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society *150 words maximum*

I was a Board member of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) from 2010-2016. From 2011-2014, I was the Coordinator of the Translational Research Committee of the HFA, and from 2014-2016 served on the Executive Committee of the HFA Board as the Chair of the Basic Science section. I have organized the prestigious Heart Failure Winter

Research Meeting in Les Diablerets in four consecutive years (2013-2016). Since 2015, I am a Fellow of the HFA of the ESC.

Since 2018, I serve on the Council of the International Society of Heart Research (ISHR), European Section (ES). In 2020, I became President-elect and in 2023, took office as President of ISHR-ES.

On a National level, I have been the chair of the Working Group of Myocardial Function and Energetics of the German Cardiac Society (DGK; 2011-2013) and has established and maintained for 10 years the DGK Basic Science Meeting. From 2015 to 2019, I served on the Programme Committee of the DGK. Currently, I am Congress President of the DGK Annual Meeting, which will take place in early April.

Why are you motivated to join the HFA Board or Nominating Committee?

150 words maximum

The HFA emerged out of the ESC Working Group for Heart Failure, and in the founding years, a balance between basic and clinical research was maintained. During my time on the HFA Board, I always strived to connect basic to clinical science. During my years on the board, the HFA Winter Research Meeting was already the premier basic heart failure meeting in Europe, while the HFA Congress was not well attended by basic scientists. Since the HFA Congress in Seville in 2015, we changed the session concept to develop a rather translational track in which basic scientists explain the mechanisms of disease and drugs to physicians, strengthening the communication between both specialties. The success of this format encouraged us to maintain this concept in the years thereafter, attracting an increasing number of basic scientists to the main congress. By serving on the Nominating committee, I would like to influence the selection of candidates towards those leaders in the field who can manage to attract more basic scientists to the HFA.

How will you combine your HFA position with your daily clinical/research workload? 80 words maximum

In my position as the spokesperson of the Comprehensive Heart Failure Center, it is part of my job description to shape heart failure research not only in Würzburg and Germany, but also internationally. I have sufficient flexibility to integrate the tasks of the nominating committee in my job.